Tenpoint Therapeutics Secures $235

Tenpoint Therapeutics, Ltd., a biotech company focused on developing treatments to rejuvenate vision, has secured $235.0 million in new investment capital.

This funding round marks a significant milestone for the company as it progresses its pipeline of ophthalmic therapies aimed at addressing conditions in the aging eye.

The company specializes in groundbreaking treatments for ophthalmic indications with high unmet need and global market potential, including presbyopia, cataracts, and geographic atrophy.

Its lead asset, BRIMOCHOL PF, is an investigational therapeutic designed to correct the loss of near vision associated with presbyopia, a condition affecting nearly 128 million people in the U.S.

Tenpoint Therapeutics has completed two large Phase 3 pivotal trials for BRIMOCHOL PF, BRIO-I and BRIO-II, and has filed a New Drug Application (NDA) with the US FDA.

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026, for BRIMOCHOL PF.

The company's leadership team comprises ophthalmic industry veterans with a history of successful approvals and commercialization of significant treatments.

The $235.

0 million in capital raised will be instrumental in advancing Tenpoint Therapeutics' innovative pipeline and supporting its strategic growth initiatives.

This investment is expected to fuel the continued development of its therapeutic candidates and prepare for potential commercialization efforts, particularly as BRIMOCHOL PF moves closer to a potential regulatory decision.

The funding underscores investor confidence in the company's scientific approach and its potential to deliver paradigm-shifting treatments to patients.

With this substantial financial backing, Tenpoint Therapeutics is positioned to accelerate its mission of bringing novel vision-rejuvenating treatments to market.

The company aims to solidify its leadership in ophthalmic care, continuing its work to address significant unmet needs in eye health and improve the quality of life for millions affected by age-related vision conditions.